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Introduction
Cushing disease (CD) is a serious endocrine disorder character-
ized by hypercortisolism caused by chronic adrenocorticotropic 
hormone (ACTH) hypersecretion from tumors of pituitary ori-
gin (primarily adenomas).1 Morbidities associated with CD 
may include diabetes mellitus, obesity, dyslipidemia, infection, 
myopathy, hypertension, thrombosis, hypokalemia, psychosis, 
depression, and fatigue.2-4 Given the clinical and biochemical 
heterogeneity of the disease,5-8 establishing a definitive diagno-
sis remains challenging,9,10 as does initiating effective treatment 
to control symptoms,11 and manage disease recurrence.12 When 
diagnosis is delayed and/or treatment is suboptimal, mortality is 
increased, with death commonly attributed to sepsis, cardiovas-
cular events (eg, myocardial infarction, stroke, pulmonary embo-
lism), or other systemic complications.4
Once CD is diagnosed, the optimal first-line treatment, if 
feasible, is transsphenoidal adenomectomy.11,13 The median 
rate of remission following initial transsphenoidal surgery 
(TSS) is 78.7%; however, rates vary widely.13 A recent large, 
multicenter, retrospective US study of adult patients with CD 
reported a remission rate of only 41% with initial pituitary 
surgery despite being operated on by experienced surgeons.2 
Regardless, even in patients who achieve surgical remission, 
recurrence of hypercortisolism remains a lifelong risk.13 Among 
patients who obtained initial remission, disease recurrence 
rates range from 0 to 65.6% (median rate 10.6%).13 The 5-year 
recurrence rate for hypercortisolism among patients with CD 
who achieve immediate surgical remission is 26%.14
While prompt surgical intervention is warranted, uncon-
trolled comorbidities are associated with surgical risks (eg, infec-
tions, thromboembolic events).13,15 Furthermore, the emergence 
of coronavirus disease-2019 (COVID-19), along with regional 
measures to reduce transmission (eg, stay-at-home orders, holds 
on elective procedures, travel restrictions) and clinical guidance 
to mitigate the risk of transmission in patients with Cushing 
syndrome (CS),16-18 may warrant surgical delays.
Radiation therapy may be used in cases of disease persis-
tence, surgical failure, or disease relapse, with a reported mean 
remission rate of up to 70.7%;13 however, onset of treatment 
effect may be delayed for years with this treatment modality, 
and hypopituitarism is a common side effect that can occur 
years following treatment.13,19 Medical therapies, including 
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pituitary-directed drugs, steroid synthesis inhibitors, and glu-
cocorticoid receptor-directed drugs, are another feasible option 
to treat persistent CD following failed surgery,11,13 to manage 
disease recurrence,11,13 to preempt surgical complications by 
controlling severe hypercortisolism,13 and to bridge the delay 
of radiation effects.11,13 Although published data are lacking, 
medical treatment may also be useful for confirming sympto-
matic recurrent hypercortisolism prior to surgical intervention 
in patients with equivocal biochemical and radiological find-
ings,20,21 and treating patients during the COVID-19 pan-
demic when it may be appropriate to delay transsphenoidal 
pituitary surgery.16-18,22 Each drug is associated with a specific 
safety and efficacy profile.
Mifepristone is a competitive GR antagonist approved by 
the US Food and Drug Administration for adult patients with 
endogenous hypercortisolism (CS), including CD, who have 
glucose intolerance or type 2 diabetes mellitus and have failed 
or are not candidates for surgery.23 Mifepristone is not a treat-
ment for type 2 diabetes mellitus in patients without endoge-
nous hypercortisolism. Clinically significant improvement with 
mifepristone was achieved in 87% of patients in the SEISMIC 
study.24 Treatment and adverse effects associated with mife-
pristone include cortisol withdrawal symptoms, antiprogester-
one effects, changes in thyroid function, and hypokalemia.24
We present a series of 6 patients with CD from multiple 
centers in whom mifepristone therapy was used as adjunct/
bridge therapy in the following clinical settings: to assess clini-
cal benefits of treatment for suspected recurrent CD, for pre-
operative control of hypercortisolemic effects, and as an 
adjunctive treatment to radiation therapy. These cases detail 
unique treatment courses for complex clinical scenarios that 
healthcare providers may encounter when managing patients 
with CD.
Consent
Institutional Review Board approval was not required by the 3 
pituitary centers where these cases were documented. Informed 
consent was obtained from each patient. Laboratory and diag-
nostic findings for all cases are presented in the tables.
Cases
Case 1: Mifepristone as part of a strategy to detect 
recurrence and assess clinical benefit of treatment
A 34-year-old woman, diagnosed 3 years prior with CD when 
she developed weight gain, acne, hirsutism, amenorrhea, and 
altered cognition, presented with concerns of recurrence. At 
her initial diagnosis, no pituitary lesion was seen on magnetic 
resonance imaging (MRI); however, inferior petrosal sinus 
sampling (IPSS) indicated a central source of ACTH, and 
pituitary surgery was successfully performed. Pathology con-
firmed an ACTH-positive pituitary adenoma. She developed 
postoperative adrenal insufficiency, and the function of her 
hypothalamic-pituitary-adrenal (HPA) axis returned after 
being on hydrocortisone replacement for 2 years.
At recent presentation, her symptoms included profound 
fatigue, cognitive and mood changes, nausea, night sweats, 
amenorrhea, and weight gain (Table 1). Repeated 1-mg dexa-
methasone suppression testing (DST) demonstrated unsup-
pressed cortisol, but 24-hour urinary free cortisol (UFC) and 
late-night salivary cortisol (LNSC) were normal (Table 1). Her 
pituitary MRI revealed no detectable abnormalities, but given 
the return of signs/symptoms similar to her initial presentation 
at diagnosis and the 1-mg DST cortisol results, medical ther-
apy with mifepristone was initiated (300 mg/day for 2 weeks 
titrated to 300 mg/day and 600 mg/day on alternating days) for 
presumptive recurrence of CD. Within 8 weeks of treatment, 
she reported improvement in symptoms of nausea, fatigue, and 
cognitive disturbance. After 4 months of treatment, mifepris-
tone was discontinued for 2 weeks for repeat biochemical test-
ing and for assessment of symptom recurrence. A 1-mg DST 
and a dexamethasone-suppressed corticotropin-releasing hor-
mone stimulation test (Dex-CRH) were both indicative of CD 
recurrence, whereas UFC, LNSC, and repeat pituitary MRI 
were all normal (Table 1). She reported a return of her symp-
toms during the 2 weeks off mifepristone; therefore, mifepris-
tone was restarted, which was followed by resolution of 
symptoms. The abatement and return of symptoms while being 
on and off mifepristone suggested recurrent CD. She contin-
ued treatment for 7 months but experienced vaginal bleeding as 
a result of the antiprogesterone effects of mifepristone. The 
patient eventually elected to undergo a bilateral adrenalectomy 
(BLA) to treat her recurrent CD, as she wished to avoid the 
risks of hypopituitarism with fractionated radiation in the 
absence of visible tumor. She now receives glucocorticoid and 
mineralocorticoid replacement therapy to treat her adrenal 
insufficiency.
Case 2: Mifepristone prior to pituitary surgery in a 
patient with bilateral pulmonary emboli
A 36-year-old man presented with fatigue, ecchymoses, muscle 
wasting, facial swelling, and palmar erythema. Additionally, he was 
found to have new-onset type 2 diabetes (65 units/day of insulin 
initiated), resistant hypertension despite treatment with 4 antihy-
pertensives, and severe hypokalemia (200 mg spironolactone and 
160 mEq potassium chloride initiated) (Table 2). He was receiv-
ing anticoagulation therapy for extensive deep venous thromboses 
and pulmonary emboli. Biochemical testing confirmed the suspi-
cion of severe hypercortisolism based on markedly elevated UFC 
and abnormal 1-mg DST (Table 2). MRI of the pituitary gland 
revealed a subtle, 6-mm hypoenhanced area. However, given the 
patient’s abrupt development of hypercortisolism, with an 
extremely elevated 24-hour UFC of 13,943 µg/day (38,483 nmol/
day), there was concern that the patient may have an ectopic 
source of ACTH production. Because of concerns 
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Table 1. Case 1: Diagnostic strategy to detect CD recurrence.
Case summary: Presentation: 34-year-old woman with history of CD (TSS 3 years prior) presented with 
profound fatigue, changes in cognition and mood, nausea, night sweats, and 69.8 kg 
weight gain in 1 year (BMI 28.5 mg/kg2). Pituitary MRI negative; biochemical 
assessments equivocal.
Treatment course: Mifepristone started (300 mg/day titrated to alternating 300/600 mg/
day). After 8 weeks, symptoms improved. After 4 months, treatment paused for repeat 
testing, revealing abnormal 1-mg DST and Dex-CRH results. During 2-week pause, 
symptoms returned. Mifepristone restarted and symptoms abated. After 7 months of 
treatment, she experienced vaginal bleeding and underwent BLA.
BIOCHEMICAL fINDINgS INITIAL CD DIAgNOSIS BEfORE MIfEPRISTONE 
(3 YEARS AfTER TSS)
RETEST AfTER 
MIfEPRISTONE PAUSE
Cortisol after 1-mg DST, μg/dL (normal <1.8 μg/dL) 22 pre-op; 4 post-op 2.8-6.1 5.1
UfC, μg/d (normal 3.5-45 μg/d) 159 19 19
LNSC, µg/dL (normal <0.10 μg/dL) <0.05 0.07
ACTH, pg/mL (normal 10-60 pg/mL) 29 15 28
Dex-CRH, cortisol, µg/dL (normal post-15 min: 
<2.5 μg/dL); ACTH, pg/mL (normal post-15 min: 
<27 pg/mL)
−5 min: cortisol 1.9; ACTH 9.1
 0 min: cortisol 1.8; ACTH 8.8
 15 min: cortisol 4.5; ACTH 28
 30 min: cortisol 8.8; ACTH 26
 45 min: cortisol 93; ACTH 31
 60 min: cortisol 11; ACTH 38
To convert cortisol and LNSC to nmol/L, multiply by 27.6. To convert UfC to nmol/d, multiply by 2.76. To convert ACTH to pmol/L, multiply by 0.22.
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; CD, Cushing disease; Dex-CRH, dexamethasone-suppressed corticotropin-releasing 
hormone stimulation test; DST, dexamethasone suppression test; HbA1c, glycated hemoglobin; LNSC, late-night salivary cortisol; TSS, transsphenoidal surgery; UfC, 
urinary free cortisol.
Table 2. Cases 2 and 3: Presurgical symptom control.
CASE 2 CASE 3
Case 
summary:
Presentation: 36-year-old man presented with fatigue, 
ecchymoses, muscle wasting, facial swelling, and palmar 
erythema.
Presentation: 59-year-old woman (BMI 33.61 kg/m2) 
presented with unexplained bruising, abdominal striae, 
lower extremity edema despite furosemide, proximal 
weakness necessitating a motorized scooter and cane for 
ambulation, progressively worsening memory, 
concentration, and irritability; hirsutism; alopecia; and an 
infected joint on left index finger that required amputation.
Past medical history/work-up: New-onset T2DM (HbA1c 10% 
[79.5 mmol/mol]); uncontrolled hypertension (BP 
140/95 mmHg); severe hypokalemia (2 mEq/L). Patient was 
receiving anticoagulation for extensive venous thromboses 
and bilateral pulmonary emboli.
Past medical history: T2DM (HbA1c 6.9% [47.6 mmol/mol]), 
controlled hypertension (BP 105/70 mmHg); hyperlipidemia, 
osteoporosis, nephrolithiasis, obesity, chronic cellulitis, and 
recent sepsis resulting from abscess development after 
lumbar spine surgery for spinal stenosis.
Treatment course: Mifepristone was started (300 mg/d) for 
5 wk before surgery. During treatment, patient lost 6.8 kg; 
several medications were eliminated or reduced. 
Mifepristone discontinued. Patient underwent TSS 2 wk later.
Treatment course: Mifepristone was started (300 mg/d). 
Treatment paused twice for scheduled surgeries. Treatment 
resumed for 11 months. Antihypertensive and antidiabetic 
medications except metformin were discontinued. She lost 
11.3 kg. Levothyroxine started for hypothyroidism; 
spironolactone started for hypokalemia. After 11 months, 
mifepristone increased to 600 mg for cushingoid symptoms. 
6 months later, underwent IPSS (positive); MRI revealed 






Increased from 53 to 98 after CRH stimulation
 (Continued)
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about suspending anticoagulation for IPSS, the patient instead 
underwent corticotropin-releasing hormone (CRH) stimulation, 
which showed an ACTH increase of >50% from baseline, sug-
gestive of CD. The following month, when the patient’s extensive 
clot burden had stabilized, he underwent IPSS, which confirmed 
a central source of hypercortisolism.
Because of the severity of his disease, mifepristone 300 mg/
day was administered for 5 weeks prior to surgery to improve 
his preoperative status. During this treatment period, he lost 
6.8 kg, his insulin requirement decreased to 5 units/day, losar-
tan and metoprolol were discontinued, and his potassium sup-
plementation decreased to 40 mEq/day.
Mifepristone was discontinued 2 weeks prior to pituitary 
surgery without a significant increase in glucose parameters or 
blood pressure. Sublabial TSS was performed, and an ACTH-
positive adenoma was resected from the left lateral aspect of his 
pituitary gland. The patient was started on empiric hydrocorti-
sone therapy (20 mg in the morning, 10 mg in the afternoon) 
immediately after surgery as per institutional protocol.
Postoperatively, insulin, hydralazine, and potassium were 
discontinued, and his spironolactone dose was reduced to 
100 mg/day. Postoperative MRI revealed surgical changes 
with the previously described hypoenhanced lesion no longer 
visible. During the 1-month postsurgical endocrine follow-up 
visit, the patient’s 8 a.m. cortisol was 4.6 µg/dL (127.0 nmol/L) 
and ACTH was 21.2 pg/mL (4.7 pmol/L). Hydrocortisone 
was tapered and stopped 18 months after his pituitary surgery. 
The patient has remained in remission from CD for 4 years 
after surgery.
Case 3: Mifepristone prior to pituitary surgery in a 
patient with recent sepsis
A 59-year-old woman reporting multiple symptoms (Table 2) 
presented for evaluation of possible CS. Her past medical his-
tory included type 2 diabetes, hypertension, hyperlipidemia, 
osteoporosis, nephrolithiasis, obesity, chronic cellulitis, and 
recent sepsis (Table 2).
CASE 2 CASE 3
Cortisol after 
DST, μg/dL
1-mg DST: 46 (normal <1.8 µg/dL) 1-mg DST: 25 (normal <1.8 µg/dL; dexamethasone level 
265 ng/dL, normal 140-295 ng/dL)
8-mg DST: 6.7 (normal >50% suppression of serum cortisol; 









ACTH, pg/mL 190 (normal 10-60 pg/mL) 102 after 1-mg DST
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To convert cortisol and LNSC to nmol/L, multiply by 27.6. To convert dexamethasone to pmol/L, multiply by 25.48. To convert UfC to nmol/d, multiply by 2.76. To convert 
ACTH to pmol/L, multiply by 0.22.
Abbreviations: ACTH, adrenocorticotropic hormone; BP, blood pressure; BMI, body mass index; CRH, corticotropin-releasing hormone; DST, dexamethasone suppression 
test; HbA1c, glycated hemoglobin; KCl, potassium chloride; LNSC, late-night salivary cortisol; MRI, magnetic resonance imaging; T2DM, type 2 diabetes mellitus; TSS, 
transsphenoidal surgery; UfC, urinary free cortisol.
Table 2. (Continued)
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Her biochemical work-up was consistent with hypercorti-
solism (Table 2), but radiographic studies revealed no evidence 
of a pituitary adenoma. Because of her susceptibility to infec-
tions, inability to heal, and recent sepsis, she was considered too 
high of a procedural risk for IPSS or other invasive procedures. 
Medical therapy with mifepristone was initiated at 300 mg/day. 
After 2 weeks of mifepristone treatment, her glimepiride was 
discontinued. Mifepristone was temporarily discontinued to 
allow urgent surgery on an infected left knee. Mifepristone was 
held for 11 days prior to the surgery, resumed 9 days postsur-
gery at 300 mg every other day for 1 month, and increased to 
300 mg/day for 2 months. She temporarily discontinued mife-
pristone treatment again 2 weeks before a scheduled right knee 
surgery for another infection; treatment was resumed 9 days 
postsurgery at 300 mg every other day for 1 week and then was 
increased to 300 mg/day. Over the course of mifepristone treat-
ment for 11 months at 300 mg/day, all antihypertensive and 
antidiabetic medications except metformin were discontinued. 
The patient lost 11.3 kg and reported resolution of her cushin-
goid signs/symptoms. She developed hypothyroidism (initi-
ated levothyroxine) and hypokalemia (initiated spironolactone 
25 mg). She was able to heal from both knee surgeries and 
ambulate independently.
After 11 months, some cushingoid symptoms returned, and 
mifepristone was increased to 600 mg/day. After 6 additional 
months, the patient was reevaluated with an IPSS (positive), and 
a hypoenhanced lesion within the left aspect of her pituitary 
gland measuring 2 × 2 × 3 mm became visible on MRI. With 
her overall health improvement on mifepristone and improved 
surgical candidacy, she underwent TSS, which removed an 
ACTH-positive left pituitary adenoma. Postoperatively, her 
nadir cortisol level was 1.3 μg/dL (35.9 nmol/L), which was sug-
gestive of disease remission. At discharge, she required hydrocor-
tisone 20 mg twice daily. At 3 months postoperatively, her 
hydrocortisone replacement was tapered to physiologic dosing 
(20 mg daily) and levothyroxine was discontinued. After 1 year 
postoperatively, she remains on hydrocortisone (10-20 mg daily) 
and metformin (glycated hemoglobin [HbA1c] 6.5% 
[47.5 mmol/mol]).
Case 4: Mifepristone during the COVID-19 
pandemic
A 53-year-old woman with ACTH-dependent CS was referred 
from her local endocrinologist for a telehealth consultation dur-
ing the COVID-19 pandemic. The patient had a long history of 
type 2 diabetes, hypertension, and obesity. Her endocrinologist 
had locally pursued an evaluation for CS the previous year fol-
lowing multiple admissions for recurrent lower extremity celluli-
tis. Baseline ACTH level was 82 pg/mL (18.0 pmol/L), cortisol 
was 37.1 µg/dL (1024 nmol/L), and 1-mg DST revealed an 
unsuppressed 8 a.m. cortisol level (17.5 µg/dL [483 nmol/L]). 
Imaging, including an MRI of the brain and computed tomog-
raphy (CT) of the chest and abdomen, did not reveal any tumor. 
Her local endocrinologist initiated mifepristone and titrated up 
to 300 mg twice daily along with spironolactone 200 mg daily. 
After 3 months of treatment, she lost 13.6 kg, and her insulin 
dosage decreased from 80 units of glargine twice a day and 
60 units of aspart 3 times a day with meals to 40 units of glargine 
twice daily and less than 10 units of aspart with meals. Her blood 
pressure control improved, and she was able to discontinue 2 of 
her antihypertensive medications.
Because of the COVID-19 pandemic, further management 
options at the tertiary care center were discussed with the 
patient via telehealth. One option included additional testing, 
involving discontinuation of mifepristone followed by IPSS 
and possible pituitary surgery. However, achieving surgical 
remission in the absence of a visible tumor was considered 
challenging. The patient had additional concerns about pursu-
ing surgery given the uncertain course of the COVID-19 pan-
demic. Moreover, the need for postsurgical assessment and 
management, which often includes a steroid taper until recov-
ery of endogenous pituitary and adrenal function is confirmed, 
would require additional office visits, unnecessarily exposing 
the patient to potential COVID-19 infection. Since her 
comorbidities had improved during mifepristone treatment, an 
alternative option to continue medical management of hyper-
cortisolism and reconsider IPSS, repeat MRI, and possible sur-
gery in the following year was discussed. After reviewing her 
options, she elected to continue mifepristone.
Case 5: Mifepristone prior to gamma knife (GK) 
radiosurgery
A 21-year-old woman presented with possible recurrent CD. 
Two years prior, she was diagnosed with CD in the context of 
morbid obesity, hypertension, poorly controlled type 2 diabetes, 
and acanthosis nigricans. At that time, her 24-hour UFC was 
elevated at 107 µg/day (295 nmol/day), LNSC was 0.586 µg/
dL (16.2 nmol/L), DHEAS was 853 µg/dL (23 µmol/L), and 
ACTH was 88 pg/mL (19 pmol/L). MRI revealed a subtle area 
of hypoenhancement in the far-right lateral aspect of her pitui-
tary gland contacting the medial aspect of the cavernous inter-
nal carotid artery, which decreased in size following TSS. Her 
surgical specimen stained positive for ACTH and had a low 
MIB-1 labeling index.
Three months after TSS, she had lost 9 kg, and her men-
strual cycle had returned. She was tapered to a single medica-
tion for hypertension, her insulin requirements had diminished 
(30 units/day), and her total daily dose of hydrocortisone was 
15 mg daily.
However, 10 months post TSS, she had regained 13.5 kg 
(total weight 145 kg; body mass index [BMI] 60.8 kg/m2) and 
her blood pressure (BP) (147/83 mmHg; spironolactone, 
hydrochlorothiazide, lisinopril) and glycemic control (HbA1c 
9.8% [83.6 mmol/mol]) had worsened. Her 24-hour UFC 
measurements ranged between 75 and 85 μg/day (207.0-
234.6 nmol/day).
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After discussing treatment options for recurrent CD, the 
patient elected to undergo GK radiosurgery for the residual tumor 
in her right cavernous sinus. She was counseled on the potential 
implications of radiosurgery for future fertility and anterior pitui-
tary hormone function. One month prior to radiosurgery, mife-
pristone was initiated at 300 mg/day and was titrated to 900 mg/
day over 12 months as bridge therapy until the effects of radiosur-
gery could be demonstrated. During mifepristone treatment, her 
insulin requirements decreased from 130 to 22 units/day, while her 
HbA1c decreased from 9.8% (83.6 mmol/mol) to 6.5% 
(47.5 mmol/mol). She lost 18 kg over 12 months. Hypokalemia 
developed during mifepristone treatment and was managed with 
spironolactone 100 mg twice/day and potassium chloride 40 mEq 
3 times/day. She remained on 3-drug antihypertensive therapy 
during mifepristone treatment, with sporadic hypertension associ-
ated with antihypertensive medication nonadherence. Two years 
after radiosurgery, the residual tumor in the right cavernous sinus 
(measuring 9 mm anteroposterior × 5 mm transverse × 3 mm 
craniocaudal on baseline postsurgical imaging) regressed and was 
nearly undetectable on 3T MRI.
While stereotactic radiosurgery improved her tumor bur-
den, she did not experience glucocorticoid withdrawal or fur-
ther clinical improvement (eg, reduction in insulin requirement 
or weight), indicating persistent ACTH production. She did 
not acquire any new anterior pituitary hormonal deficits fol-
lowing GK radiosurgery. She remained on mifepristone 900 mg 
daily and contemplated undergoing BLA at last contact.
Case 6: Mifepristone after GK radiosurgery
A 32-year-old woman presented for evaluation of persistent 
CD following an unsuspected diagnosis of CD approximately 
1 year prior during an evaluation for bilateral galactorrhea. 
Among her many cushingoid symptoms, she reported precipi-
tous weight gain (38 kg in 1 year), edema, visual disturbances, 
skin lesions, and recurrent infections. Also present were hyper-
prolactinemia (prolactin 45.6 ng/mL [2.0 nmol/L], upper limit 
of normal [ULN] 26.0 ng/mL [1.1 nmol/L]) and unsuppressed 
cortisol levels after 1-mg DST. Brain MRI revealed a pituitary 
mass measuring 1.8 × 2.1 × 1.6 cm with left cavernous sinus 
invasion and compression of her optic chiasm.
After undergoing TSS that removed an ACTH-positive 
pituitary adenoma, her cortisol levels did not drop sufficiently. 
The patient desired surgery rather than medical treatment. 
Future fertility was not a concern for her; therefore, a total 
hypophysectomy was undertaken. Postsurgical cortisol was 
5.23 μg/dL (144.3 nmol/L), and hydrocortisone replacement 
20 mg twice daily was prescribed. She noted improvements in 
dermatological lesions, edema, and vision (left eye); however, 
she developed growth hormone deficiency (received growth 
hormone 0.2 mg), diabetes insipidus (received desmopressin 
0.2 mg), hypothyroidism (received levothyroxine 150 μg/day), 
and hypogonadism. Her hydrocortisone dose was 15 mg/day.
Six months after surgery, the patient was found to have pre-
diabetes, hypertension, and weight gain, as well as various 
symptoms and laboratory measures characteristic of CD recur-
rence (Table 3). Brain MRI revealed a residual enhancing 
tumor within the left aspect of the sella and the left cavernous 
sinus with encasement of the left internal carotid artery of 
approximately 75% of its circumference. The residual tumor 
measured maximally 1.4 × 1.7 × 1.4 cm and extended mini-
mally into the suprasellar space.
She underwent GK radiosurgery, and 2 weeks later, mife-
pristone was initiated at 300 mg/day as adjuvant therapy. After 
1 month of treatment, her potassium was 3.6 mmol/L (normal 
range 3.5 mmol/L-5.2 mmol/L); 50 mg/day spironolactone 
was initiated. Free thyroxine decreased to 1.27 ng/dL (16.34 
pmol/L; normal range 0.82-1.77 ng/dL [10.6-22.8 pmol/L]), 
so levothyroxine was increased to 175 μg/day. She experienced 
mild symptoms of cortisol withdrawal, which resolved 2 months 
later, and mifepristone was titrated to 600 mg/day. She experi-
enced more significant cortisol withdrawal symptoms (nausea, 
vomiting, and diarrhea), and her dose was reduced to 450 mg/
day. She continued mifepristone for 8 additional months. 
During treatment, she experienced resolution of prediabetes 
(HbA1c 5.5% [36.6 mmol/mol]) and hypertension (BP 
113/75 mmHg), and lost weight (BMI decreased from 52.01 to 
41.71 kg/m2).
Although ACTH and cortisol were expected to increase on 
mifepristone treatment, her levels decreased (Table 3), suggest-
ing GK radiosurgery success; hence, mifepristone was discontin-
ued. Follow-up brain MRI 1 year after GK radiosurgery 
demonstrated that her residual tumor decreased in size and 
enhancement intensity. Ten months after discontinuing mife-
pristone, her ACTH remained normal, and cortisol remained 
low, although the cortisol increased after a cosyntropin stimula-
tion test (Table 3). Blood pressure (BP 103/64 mmHg) and glu-
cose control (FPG 68 mg/dL [3.8 mmol/L]) remained normal.
Discussion
The management of CD is often complicated by the potential 
risks of infection, uncontrolled diabetes, and/or hypertension, 
which may increase periprocedural risks.13 Postoperative manage-
ment of residual unresectable tumor, persistent hypercortisolism, 
or disease recurrence requires interventions and considerations 
regarding more invasive treatments (eg, BLA, total hypophysec-
tomy, radiation) to achieve sustained remission.13 The COVID-
19 pandemic has further affected patient care and complicated 
treatment decisions. Recent guidance recommends deferring 
extensive laboratory and imaging diagnostic work-up and transs-
phenoidal pituitary surgery during the pandemic depending on 
the patient’s clinical disease severity and lack of visual symptoms; 
they suggest incorporation of virtual telehealth visits to aid in the 
diagnosis and management of patients.17,18 These cases from 3 
pituitary centers provide real-world examples for how mifepris-
tone can be used as adjunct/bridge therapy in challenging clinical 
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care settings to treat hypercortisolism while other treatment deci-
sions are being considered.
Mifepristone as part of a strategy to detect 
recurrence and assess clinical benefit of treatment
Although the 2008 Endocrine Society guidelines outline the 
investigative strategy for the diagnosis of CD,9 currently no 
clear consensus exists regarding the most appropriate test(s) 
for the diagnosis of recurrent CD.10,25 The management of 
patients who present with recurrent, but not definitive clinical 
features in the context of equivocal biochemical is particularly 
challenging.21 The use of a therapeutic trial in patients with 
suspected CD recurrence who have equivocal biochemical 
workup, in order to determine if a more definitive treatment 
approach should be considered, has been previously proposed 
and warrants further prospective clinical evaluation.20,21
Therapeutic trials to establish/support a diagnosis have long 
been used for other endocrinopathies; for example, spironolac-
tone has been used historically as an empirical treatment to 
distinguish primary from secondary aldosteronism and to pre-
dict who might benefit from adrenal surgery;26 and prednisone 
and methimazole have been used to treat amiodarone-induced 
thyroiditis when the type (type 1, type 2, mixed type) is in 
question.27
In Case 1, the patient presented with recurrence of her present-
ing features of CD and demonstrated lack of suppression on two 
1-mg DSTs, but had normal LNSC and 24-hour UFC, suggesting 
early disease recurrence. A therapeutic trial of mifepristone was ini-
tiated, which resulted in symptomatic improvement. With time, 
repeated testing confirmed recurrent CD and the patient opted to 
undergo BLA to avoid hypopituitarism with fractionated radiation 
or total hypophysectomy. Although BLA offers definitive treat-
ment of hypercortisolism, it results in permanent adrenal insuffi-
ciency, requiring lifelong glucocorticoid and mineralocorticoid 
replacement.13 While the use of a therapeutic trial in equivocal 
cases of CD is an area that requires further study, this case shows 
that medical treatment with mifepristone to manage symptoms 
may be useful during the ongoing evaluation of therapeutic options 
for recurrent or persistent CD, with awareness that treatment goals 
and patient preferences may change over time.
Medical therapy as preoperative treatment to 
control hypercortisolemic effects
Mortality from uncontrolled CD-associated hypercortisolism is 
largely attributed to cardiovascular disease and its consequent 
events, thrombotic events resulting from a hypercoagulable 
state, and/or systemic infections that often lead to fulminant 
septicemia.28-31 Reducing the risk of such sequelae is vital, 
given that surgery tends to amplify these risks.13,15 Susceptibility 
to opportunistic infections due to glucocorticoid-induced 
immunosuppression is characteristic of CD4,32 and can be 
improved with effective treatment.4,33 However, to date, data 
supporting the potential benefits of preoperative treatment of 
hypercortisolism on surgical outcomes are lacking.34
Table 3. Case 6: Bridging therapy for radiosurgery for recurrent CD.
Case summary: Presentation: 32-year old woman with history of CD (post TSS, total hypophysectomy 1 y prior) presented 
with weight gain (BMI 52.01 kg/m2), scalp lesions, dorsocervical and supraclavicular fat deposition, facial 
rounding, hirsutism, pulsating headaches, edema, anxiety, poor memory, and low energy.
Work-up: Prediabetes (HbA1c 6.5% [47.5 mmol/mol]) and hypertension (BP 132/78 mmHg, treated with 
triamterene/hydrochlorothiazide). MRI positive for residual tumor.
Treatment course: Patient underwent gK radiosurgery followed by mifepristone (300 mg/day titrated to 
max-tolerated dose of 450 mg/day). After 1 mo, spironolactone added for low-normal potassium 
(3.6 mmol/L). Levothyroxine increased to 175 µg/day. During the following 10 months of treatment, her 
prediabetes (HbA1c 5.5%) and hypertension (BP 113/75) resolved, and she lost weight (BMI 41.71 kg/m2). 
ACTH and cortisol decreased; mifepristone was discontinued. MRI showed decrease in residual tumor size. 
Ten months after mifepristone discontinuation, BP (103/64 mmHg) and glucose control (fPg 68 mg/dL) 
remained normal.
BIOCHEMICAL fINDINgS BEfORE gK RADIOSURgERY/
MIfEPRISTONE
DURINg MIfEPRISTONE BRIDgE 
(AfTER RADIOSURgERY)
POST-MIfEPRISTONE
Serum cortisol, μg/dL (normal 
7-25 μg/dL)
12.3, 21, 23.9 7.4 7.3
15.3 after cosyntropin 
stimulation test
LNSC, µg/dL (normal <0.09 μg/
dL)
0.16, 0.41, 0.44, 0.31 on repeat 
testing
― ―
ACTH, pg/mL (normal 7.2-63.3 
pg/mL)
99 47.9 34.0
To convert cortisol and LNSC to nmol/L, multiply by 27.6. To convert UfC to nmol/d, multiply by 2.76. To convert ACTH to pmol/L, multiply by 0.22.
Abbreviations: ACTH, adrenocorticotropic hormone; BP, blood pressure; BMI, body mass index; CD, Cushing disease; fPg, fasting plasma glucose; gK, gamma knife; 
HbA1c, glycated hemoglobin; LNSC, late-night salivary cortisol; MRI, magnetic resonance imaging; TSS, transsphenoidal surgery; UfC, urinary free cortisol.
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Case 2 illustrates the ability of mifepristone to control the 
effects of severe hypercortisolism and reduce the risk of perio-
perative complications in a patient with CD who presented 
with resistant hypertension, history of pulmonary emboli, and 
diabetes. The patient’s disease manifestations were effectively 
stabilized and hypokalemia was effectively managed with 
spironolactone, enabling the patient to undergo the preferred 
surgical intervention. In the SEISMIC trial that included 50 
adult participants on mifepristone therapy for CS, 44% devel-
oped hypokalemia, which responded to potassium supplemen-
tation (10-420 mEq daily) and the use of mineralocorticoid 
antagonist therapy (spironolactone: 50-400 mg daily).24
Case 3 describes a complicated patient with high suscepti-
bility to infectious complications, who, after mifepristone 
treatment, was able to undergo 2 knee surgeries without wors-
ening infection or development of sepsis. She experienced fur-
ther clinical benefit with mifepristone prior to surgery for CD 
that included improvements in ambulatory capacity, and glyce-
mic and blood pressure control. In line with our case series, 
there have been other reports of symptom management bene-
fits with the use of mifepristone in patients with hypercorti-
solism prior to surgery.13,35-37 Additionally, in Case 3, the 
pituitary tumor became visible during the interval period of 
medical therapy, allowing more targeted surgery, which may 
increase the likelihood of long-term remission. Mifepristone 
has been shown to increase ACTH levels.38 The increase in 
ACTH levels with mifepristone and its effects on ACTH-
secreting tumor progression is not yet well understood. 
Follow-up data from the SEISMIC study noted both regres-
sion and progression of pituitary tumors with mifepristone 
treatment.38 Regression occurred in 2 patients (1 macroade-
noma after radiotherapy and 1 microadenoma), and progres-
sion occurred in 3 patients with macroadenomas (2 after 
radiotherapy). Progression has also occurred in a patient with 
an initial nonvisible tumor; however, whether tumor growth 
was related to the drug or the natural history of the pituitary 
adenoma itself is unknown.38
Case 4 describes a patient diagnosed with ACTH-
dependent CS during the COVID-19 pandemic. No tumor 
had been visualized, and her comorbidities were being medi-
cally managed with mifepristone therapy. Preoperative coun-
seling for pituitary surgery included detailed discussion about 
the postoperative likelihood of remission and hypopituitarism, 
the experience of steroid withdrawal symptoms, and the man-
agement of a potentially long glucocorticoid taper until endog-
enous pituitary function resumes. Telehealth consultation has 
improved our ability to communicate with patients and direct 
therapy during the uncertainty of the COVID-19 pandemic, 
especially when considering travel and surgery at tertiary pitui-
tary specialty care centers. With the additional risk concerns 
for COVID-19 transmission and complications during the 
pandemic, patients and providers may consider medical ther-
apy for CD more often as a presurgical option,16-18,22 
particularly when a tumor is not visible. In this case, the patient 
was able to discuss management options via telehealth and 
subsequently decided to continue medical treatment of her 
hypercortisolism while planning to reconsider additional test-
ing in another year, with the hope that during the interval 
period, the tumor may become visible on follow-up imaging, as 
occurred in Case 3. This case demonstrates the importance of 
shared decision-making when treating patients with hypercor-
tisolism and shows that it can occur successfully using tele-
health medicine during the COVID-19 pandemic. Interval 
preoperative medical therapy might also facilitate postopera-
tive recovery of the HPA axis, decreasing the need for or dura-
tion of glucocorticoid replacement therapy after surgery as 
described in adrenal CS.36 However, one must consider the 
potential effects of preoperative medical treatment on the 
interpretation of surgical success, as medical treatment may 
confound the immediate postoperative cortisol assessment.34
Medical therapy during the latency interval of 
radiotherapy
The mean time to initial remission varies from 3 to 58.3 months 
with stereotactic radiotherapy13,19,39 and from 10.2 to 24 months 
with conventional radiotherapy;13,40,41 thus, adjuvant medical 
therapy during this latency period is essential. In Cases 5 and 6, 
mifepristone was administered as adjunct therapy to radiation 
therapy. Case 5 describes a patient with recurrent disease, and 
Case 6 describes a patient with incomplete response following 
pituitary surgery. Treatment with mifepristone led to a reduction 
in weight and HbA1c in both cases, as well as resolution of hyper-
tension in the latter. In Case 5, hypokalemia developed but was 
adequately managed with potassium supplementation and 
spironolactone. In Case 6, spironolactone was initiated during 
mifepristone treatment after a low-normal potassium level 
(3.6 mEq/L) was recorded, in order to proactively prevent an epi-
sode of hypokalemia, since mifepristone can exacerbate the risk of 
hypokalemia.24 A similar proactive approach to mitigating the risk 
of hypokalemia has been suggested based on consensus recom-
mendations for the management of patients treated with mife-
pristone from clinical practice.42 These recommendations included 
consideration of potassium supplementation and concomitant 
spironolactone for patients with baseline potassium levels less than 
4 mEq/L followed by monitoring during and after mifepristone 
titration.42 The patient in Case 6 also had a history of central 
hypothyroidism. Substantial increases in thyroid hormone require-
ment (median levothyroxine dose increase 1.83 times initial dose) 
have been documented during mifepristone treatment in patients 
with CD and central hypothyroidism.43 Free thyroxine (T4) levels 
should be monitored in patients with central hypothyroidism 
before and during mifepristone treatment.42 In this case, a clinical 
treatment decision was made to slightly increase the patient’s dose 
of levothyroxine during mifepristone treatment following an 
observed decrease in free T4 levels.
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As ACTH levels typically increase during mifepristone 
treatment, when a decline in cortisol and ACTH levels was 
observed in Case 6, it was a signal that the GK radiotherapy 
had been successful, and mifepristone was discontinued. 
Whether mifepristone and its associated changes in ACTH 
affect the outcome of radiotherapy itself remains to be deter-
mined, and its adjunctive use before and after radiotherapy in 
patients with CD has yet to be formally studied.
Conclusions
This case series highlights the utility and effectiveness of mife-
pristone therapy in patients with CD in perisurgical and per-
iradiation settings, where its use alleviated various clinical 
manifestations, including improvements in glycemic and blood 
pressure control, and weight reduction. In particular, during the 
COVID-19 pandemic, mifepristone may also be considered to 
treat the effects of hypercortisolism when surgical delays occur. 
The potential for mifepristone to be used as a therapeutic trial 
in patients with suspected recurrent hypercortisolism whose 
presentation is mild or biochemically inconclusive until defini-
tive diagnosis and therapeutic strategies can be implemented 
should be further evaluated in a large prospective clinical study.
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